Heart attacks could be reduced by rethinking the way we prescribe statins

Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications. The findings, which are published online in Circulation, the journal of the American Heart Association, could improve prevention of heart disease, especially in younger people.

"Our study is changing the way we think about prescribing statins; we should not only be considering who is at risk of heart disease but, more importantly, who would benefit from these medications," says study-lead author, Dr. George Thanassoulis, who is the director of Preventive and Genomic Cardiology at the MUHC and an associate professor in Medicine at McGill University. "For example, younger patients who have high cholesterol, are frequently considered too young to be at risk for heart attack in the short term, but our analysis shows that they would benefit from treatment, even in the short term, and therefore should be eligible for statin treatment."

The research team performed their modelling study using data from 2,134 participants from the National Health and Nutrition Examination Survey - a nationally-representative US cohort, between 2005 and 2010, representing 71.8 million Americans potentially eligible for statins. Two approaches for statin eligibility were compared: a ten-year risk based approach, currently in use, and an individualized benefit approach. The latter method of determining who should receive statins was found to produce greater eligibility.

"Using a benefit-based approach, we identified 9.5 million lower-risk Americans not currently eligible for statin treatment, who had the same or greater expected benefit from statins as higher-risk individuals," explains Dr. Thanassoulis. "These individuals were lower-risk because they were younger but they also had higher levels of low-density lipoprotein cholesterol which we have known to be an important cause of heart disease. Targeting statin treatment to this group would prevent an additional 266,000 heart attacks and strokes over 10 years,"

"This strategy will transform cardiovascular prevention for the better," adds study's co-author, Dr. Allan Sniderman, MUHC cardiologist and full professor in Medicine at McGill University. "For too many, the present approach starts too late; an earlier start will multiply the lives saved."

Dr. Thanassoulis and collaborators are now developing a Web interface to extend the use of this calculation model to physicians. Researchers hope this new way will help develop guideline recommendations that better identify individuals who meaningfully benefit from statin therapy.

This study was funded by the Fonds de recherche du Québec - Santé and by the Doggone Foundation. The paper was coauthored by George Thanassoulis and Allan D. Sniderman (Research Institute of the McGill University Health Centre and McGill University, Montreal, QC, Canada); Ken Williams (KenAnco Biostatistics and University of Texas Health Science Center, San Antonio, TX); Kathleen Kimler Altobelli (KenAnco Biostatistics, San Antonio, TX), Michael J. Pencina (Duke Clinical Research Institute, Durham, NC), Christopher P. Cannon (Harvard Clinical Research Institute and Brigham and Women's Hospital, Boston, MA).

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

FDA approves once-daily Qtern (dapagliflozin and s…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of typ...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]